Screener / SEC EDGAR /CIK 0001599298 /10-K filed Feb 23, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Summit Therapeutics Inc. SMMT

Compare with peers Embed
The 10-K against last year's

143 changes: 36 added, 36 removed, 70 reworded, 1 quiet changes

10-K Feb 23, 2026 vs Feb 24, 2025

10-K 0001599298-26-000015 (Feb 23, 2026) vs 10-K 0001599298-25-000048 (Feb 24, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

356 paragraphs · 24 new · 74 reworded · 24 gone · 10-K Feb 23, 2026 against Feb 24, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 252 · 47% changed Every version of it
Moreover, if we license technology or product candidates from third parties in the future, we may have limited control over the preparation, filing, prosecution, or enforcement of the associated patents, leaving us vulnerable to decisions that may not align with our goals or interests. For example, under our License Agreement with Akeso, patent prosecution and enforcement in the Licensed Territory are subject to consultation and cooperation with Akeso. If we cannot align on our patent strategy, this could impact the patentability or enforcement of the licensed intellectual property. Actions or statements during patent prosecution outside of the Licensed Territory could significantly influence the validity of any patent obtained within the Licensed Territory, potentially undermining our competitive position. Additionally, Akeso owned patents and patent applications, which are non-exclusively licensed to Summit under the License Agreement, are under the control of Akeso. Akeso’s prosecution, enforcement, and licensing strategies with regard to their owned patents and patent applications may conflict with our objectives.
Paragraph 150 · 43% changed Every version of it
Third-party manufacturers, including Akeso, may not be able to comply with current good manufacturing practice (“cGMP”), regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, including Akeso, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.
Paragraph 181 · 43% changed Every version of it
The U.S. and Chinese governments have taken certain actions that change trade policies, including tariffs and threats of additional tariffs that affect certain products which are manufactured in China and mutual exchange of certain types of data. Due to our collaboration with Akeso, we are reliant on collaborating with a company with significant operations in China. We do not know whether and to what extent the Trump administration will implement or alter any tariffs, laws or regulations that may increase the cost or feasibility of importing and exporting products, components and information from China to the United States and vice versa. Further, the effect of any such new tariffs or actions on our industry and customers is unknown and difficult to predict. As additional tariffs, legislation and regulations are implemented, or if existing trade agreements are renegotiated, or if China or other affected countries take retaliatory trade actions, such changes could have a material adverse effect on our clinical development plans, business, financial condition, results of operations or cash flows.
Paragraph 267 · 42% changed Every version of it
If we are found to infringe third party’s intellectual property rights, or if we choose to settle a dispute to avoid prolonged litigation, we may be required to obtain a license to enable us to continue developing and marketing our products and technology. However, obtaining such licenses may be challenging or unattainable on commercially reasonable terms. Even if we were able to obtain a license, it could be non-exclusive, which would enable our competitors access to the same technologies and we may be required to pay substantial upfront or ongoing royalties. Absent a license, we could be forced, including by court order, to cease commercializing the infringing technology or product entirely. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees, particularly if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties, or claims that we derived our inventions from another, could have a similar negative impact on our business.
Paragraph 167 · 37% changed Every version of it
Our ability to commercialize ivonescimab or any other product candidate successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Significant uncertainty exists as to the coverage and reimbursement status of any of our products for which we obtain regulatory approval. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in In the U.S. United States, although private third-party payors tend to follow Medicare practices, no uniform or consistent policy of coverage and E.U. healthcare industries reimbursement for drug products exists among third-party payors. Therefore, coverage and elsewhere reimbursement for drug products can differ significantly from payor to payor as well as from state to state. Consequently, the coverage determination process is cost containment. often a time-consuming and costly process that must be played out across many jurisdictions and different entities and that will require us to provide scientific, clinical and health economics support for
Paragraph 242 · 35% changed Every version of it
In the E.U., similar political, economic and regulatory developments may affect our ability to profitably commercialize our products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the E.U. or Member State level may result in significant additional requirements or obstacles that may increase our operating costs. An example of reform measures is the forthcoming EU pharmaceutical legislation revision, which intends to change – among other things – the regulatory data protection regime and the orphan designation regime. The final text of the reform proposal is expected to be endorsed and published in the first half of 2026 and, after a transition period, the new legislation is expected to start to apply from mid-2028.
Paragraph 336 · 29% changed Every version of it
Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our shares of common stock.
Paragraph 253 · 28% changed Every version of it
Moreover, if we license technology or product candidates from third parties in the future, we may have limited control over the preparation, filing, prosecution, or enforcement of the associated patents, leaving us vulnerable to decisions that may not align with our goals or interests. For example, under our the License Agreement with Akeso, Agreement, patent prosecution and enforcement in the Licensed Territory are subject to consultation and cooperation with Akeso. If we cannot align on our patent strategy, this could impact the patentability or enforcement of the licensed intellectual property. Actions or statements during patent prosecution outside of the Licensed Territory could significantly influence the validity prosecution of any patent obtained application within the Licensed Territory, potentially undermining our competitive position. Territory. Additionally, Akeso owned patents and patent applications, which are non-exclusively licensed to Summit under the License Agreement, are under the control of Akeso. Akeso’s prosecution, enforcement, and licensing strategies with regard to their owned patents and patent applications may conflict with our objectives.

MD&A

116 paragraphs · 12 new · 39 reworded · 12 gone · 10-K Feb 23, 2026 against Feb 24, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 30 · 42% changed
As a U.S. tax resident trading entity, we are subject to U.S. corporate taxation. Our U.K. resident trading subsidiaries are individually subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses since inception. We have recorded a full valuation allowance against the deferred tax assets with respect to these tax losses in excess of our deferred tax liabilities in each jurisdiction because we do not consider it more likely than not that there will be suitable taxable profits in the foreseeable future based on the evidence available against which to offset these losses.
Paragraph 6 · 42% changed
The Company has begun its development for is developing ivonescimab in non-small cell lung cancer (“NSCLC”), NSCLC and CRC, specifically launching conducting Phase III clinical trials in the following proposed indications:
Paragraph 8 · 38% changed
(b) ivonescimab combined with chemotherapy in patients with first-line metastatic NSCLC (including separate statistical analyses planned for patients (“HARMONi-3”) with squamous NSCLC and non-squamous NSCLC) (“HARMONi-3”);
Paragraph 7 · 34% changed
(a) ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (“EGFR”)-mutated, EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment were previously treated with a third-generation EGFR tyrosine kinase inhibitor (“TKI”) TKI (“HARMONi”); and
Paragraph 49 · 34% changed
To date, we have financed our operations primarily through issuances of our common stock, including our most recent private placement issued in September 2024 for gross proceeds of $235.0 million and the raise of $44.2 $150.7 million gross proceeds from our ATM Agreement during 2024, since inception, issuance of debt, and receipt of payments to us under license and collaboration arrangements.
Paragraph 5 · 34% changed
The Company’s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. On December 5, 2022, the Company entered into the License Agreement with Akeso pursuant to which the Company has in-licensed intellectual property rights related to ivonescimab (as amended, the “License Agreement”). Through the License Agreement, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan. The License Agreement and transaction closed in January 2023 following customary waiting periods. On June 3, 2024, the Company entered into an amendment to the License Agreement Second Amendment with Akeso to expand its territories covered under the License Agreement to also include the Latin America, including Mexico and all countries in Central America and South America, the Middle East and Africa regions (collectively, and as expanded, the "Licensed Territory"). Africa. The Company’s operations are focused on the development of ivonescimab and other future activities, as the Company determines.
Paragraph 60 · 33% changed
We have During the year ended December 31, 2025, the Company raised gross proceeds of $500,037 from a private placement and $106,498 from the Company’s at-the-market sales agreement. With these recent financings, the Company has evaluated whether our and concluded that its cash, cash equivalents and short-term investments provide sufficient cash to fund our operating cash needs for the next 12 months from the date of issuance of these annual financials. We concluded that our cash, cash equivalents and short-term investments as of December 31, 2024 will fund our its operating cash needs for at least the next 12 months from the date of issuance of these consolidated financial statements.
Paragraph 47 · 32% changed
Interest expense on promissory notes payable to related parties decreased to $8.7 million for the year ending December 31, 2024, from $16.5 million during 2025 compared to the year ending December 31, 2023, same period in the prior year, due to the repayment in full payment of the promissory note in October 2024.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Accounting Policies233 words changed in this paragraph; it is 32% similar to last year's version.
The Company assesses goodwill for impairment on an annual basis as of December 31 or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company’s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.

Source: 10-K text, Note 2 – Summary of Significant Accounting Policies and Recent Accounting Pronouncements, 10-K 0001599298-26-000015 vs 10-K text, Note 4 – Summary of Significant Accounting Policies and Recent Accounting Pronouncements, 10-K 0001599298-25-000048

Risk Factors198 words changed in this paragraph; it is 33% similar to last year's version.
Other legislative changes have been proposed and adopted since passage of the ACA. These have, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers. For example, several healthcare reform initiatives culminated in the enactment of the IRA, which includes several provisions to lower prescription drug costs for Medicare patients and reduce drug spending by the federal government. Among other things, the IRA requires HHS to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that the U.S. Centers for Medicare and Medicaid Services (“CMS”) reimburses under Medicare Part B and Part D. Negotiations will occur for high expenditure single-source biological products that have been on the market for 11 years (seven years for single-source drugs). Revised prices will take effect two years after these negotiations occur. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D products in 2023, negotiations began in 2024, and the negotiated price for each product has been announced. In addition, CMS has selected and announced the negotiated price for 15 additional Medicare Part D drugs which will become effective in 2027. For 2028, an additional 15 drugs, which may be covered under either Medicare Part B or Part D, the negotiated price will be effective, and for 2029 and subsequent years, 20

Source: Item 1A, 10-K 0001599298-26-000015 vs Item 1A, 10-K 0001599298-25-000048

MD&A140 words changed in this paragraph; it is 76% similar to last year's version.
Furthermore, on January 19, 2023, we and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties’ intent that we may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by us in the approximate amount of $500 million, or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the 2023 Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) the Duggan September Note following the completion of a capital raising transaction subsequent to the 2023 Rights Offering (as defined in Note 17 Stockholders’ Equity to the consolidated financial statements included under Item 15 Exhibits, Financial Statement Schedules) in an amount equal to the lesser of (A) the net proceeds of such capital raise or (B) the full amount outstanding of the Duggan September Note. Following the issuance of the two new Promissory Notes (the “Duggan Promissory Notes”), the Duggan February Note and Duggan September Note were marked as “cancelled” on their face and replaced in their entirety by the Duggan Promissory Notes (together with the Zanganeh Note, the “Notes”). The Notes accrued interest at an initial rate of 7.5%. All interest on the Notes was paid on the date of signing for the period through February 15, 2023. Such prepaid interest was paid in a number of shares of our common stock, par value $0.01 (“Common Stock”) equal to the dollar amount of such prepaid interest, divided by $0.7913 (the consolidated closing bid price immediately preceding the time we entered into the Note Purchase Agreement, plus $.01), which was 9,720,291 shares. For all applicable periods following February 15, 2023, interest accrued on the outstanding principal balance of the Notes at the US prime interest rate, as reported in the Wall Street Journal, plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the US prime rate plus 300 basis points, as adjusted monthly. Accrued interest was paid in cash, quarterly in arrears, on each of March 31, June 30, September 30 and December 31.

Source: Item 7, 10-K 0001599298-26-000015 vs Item 7, 10-K 0001599298-25-000048

Legal Proceedings10 words changed in this paragraph; it is 93% similar to last year's version.
The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. Most contracts provide for termination upon notice, and therefore are cancellable contracts. The majority of these commitments are due within one year. As of December 31, 2024, 2025, total unconditional purchase obligations, excluding leases commitments, are estimated to be approximately $ 13,900. 17,976.

Source: Item 3, via Note 16 – Commitments and Contingencies, 10-K 0001599298-26-000015 vs Item 3, via Note 19 – Commitments and Contingencies, 10-K 0001599298-25-000048

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of SMMT's Risk Factors and MD&A, 10-K Feb 23, 2026 against 10-K Feb 24, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
In January 2026, the FDA accepted for filing our BLA seeking approval of ivonescimab in combination with chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC post-TKI therapy and provided a PDUFA target action date of November 14, 2026. The delay or denial of regulatory approval, inability to maintain regulatory approval, inability to complete post-marketing requirements, or the requirement to resubmit any marketing application with additional data or information could mean that we otherwise negatively would delay commercialization of ivonescimab and adversely impact our ability to generate revenue, our business and our operations.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
this setting. If the FDA does not agree with our analysis of the HARMONi data, they may delay or deny regulatory approval in this proposed indication, require us to resubmit the marketing application with additional data or information, or take other actions that could delay commercialization of ivonescimab and adversely impact our ability to generate revenue, our business and our operations. We cannot predict the results of our ongoing or future clinical trials.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
Regulatory authorities have substantial discretion in the approval process. They may refuse to accept any application or may decide that our data are insufficient for approval and require additional clinical trials or other studies. In our public communications, we may designate certain of our clinical trials as “pivotal” if we believe that these clinical trials, if successful, will support BLA submissions; however, there can be no assurance that any clinical trial that we designate as “pivotal” will be viewed as sufficient by the FDA, the EMA and other comparable regulatory authorities in other jurisdictions to support regulatory approval. If we are required to conduct additional clinical trials or other testing of any of our product candidates beyond those that are contemplated, we may incur significant additional costs and regulatory approval may be delayed or prevented.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
There can be no guarantee that the FDA or other regulatory authorities will interpret the results or reach the same conclusions from the data as we do, or fully agree that our development plans are sufficient for submission or approval of a BLA. In the event that the FDA requires us to conduct clinical trials with more patients than planned, to conduct clinical trials with designs or endpoints other than we currently anticipate, we may not have the funding to enlarge or conduct such trials and we may not be able to raise sufficient funding to do so, which could delay or prevent commercialization of our product candidates. In addition, the FDA or other regulatory authorities may change their views on aspects of the clinical programs, including clinical trial designs, or the ability of the trials as designed to support approval of a product. If we are unable to effectively and efficiently resolve and comply with the inquiries and requests of the FDA and other comparable international regulatory authorities, the approval of our product candidates may be delayed, which could delay or prevent commercialization of our product candidates.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
We have conducted, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
We have conducted, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. We are currently conducting clinical trials in China, and we expect to continue to conduct trials internationally in the future. The acceptance of data from clinical trials conducted outside the United States by the FDA or other regulatory authorities may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for regulatory approval in the United States, the FDA will generally not approve the application unless (i) the data are applicable to the U.S. population and U.S. medical practice and (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations, and the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCPs and the FDA is able to validate the data from the study through an
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
onsite inspection if deemed necessary. Additionally, the FDA’s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with foreign exchange fluctuations, compliance with foreign manufacturing, customs, shipment and storage requirements, and cultural differences in medical practice and clinical research, and diminished protection of intellectual property in some countries.
Read it in 10-K Feb 23, 2026 at sec.gov
Show the other 65
AddedRisk Factors
There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. For example, for FDA acceptance, we will have to demonstrate that the foreign data are applicable to the U.S. population and U.S. medical practice. If the FDA or other regulatory authorities do not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop being delayed or not receiving approval for commercialization in the applicable jurisdiction.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
•Inability to build a marketing operations infrastructure with the development of advance analytics allowing for different channels to be utilized for promotions beyond the sales organization
Read it in 10-K Feb 23, 2026 at sec.gov
RemovedRisk Factors
design and execute a clinical trial to support marketing approval. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. To date, we have not completed a clinical trial for ivonescimab in the Licensed Territory and cannot predict the results of such trials.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the applicable regulatory authority. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs,
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
From time to time, U.S. federal, state and non-U.S. legislation has been proposed that would, if enacted into law, make significant changes to tax laws, including certain key U.S. federal, state and non-U.S. income tax provisions currently applicable to companies like us. It is unclear whether these or similar changes will be enacted and, if enacted, how soon any such changes could take effect. The passage of any legislation as a result of these proposals and other changes in tax laws or the imposition of new or increased taxes or fees could affect our effective tax rates in countries where we have operations and could have an adverse effect on our overall tax position in the future, along with increasing the complexity, burden and cost of tax compliance, in each case potentially increasing our future tax liabilities and adversely affect our operating results and cash flows.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
Recent changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act (the “TCJA”), which significantly reformed the Code. The TCJA, among other things, contained significant changes to corporate taxation, including certain limitations on interest deductions, limitations of the deduction for certain net operating losses, and the modification or repeal of many business deductions and credits.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
Beginning with costs incurred in 2022, the TCJA also eliminated the option to deduct research and development expenditures and requires taxpayers to capitalize and amortize them over five or fifteen years. If this requirement is not modified, it may impact our effective tax rate and our cash tax liability in future years. More recently, the IRA contained, among other things, a corporate alternative minimum tax, which imposes a 15% minimum tax will be imposed on certain financial statement income of “applicable corporations” in taxable years beginning after December 31, 2022. The IRA also imposes a 1% non-deductible excise tax on the fair market value of any stock repurchased by a publicly traded domestic corporation during any taxable year, with the fair market value of such repurchased stock reduced by the fair market value of certain stock issued by such corporation during such taxable year.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
Recent announcements of changes in the U.K. research and development (“R&D”) regime are likely to impact the level of cash benefit that the Company will be able to receive in respect of the R&D activity. As a result of a reduction in rates applied in the Small and Medium Enterprise (“SME”) regime, the cash credit that the Company will be able to obtain is likely to reduce if the qualified spending remains consistent. This will be partly offset by an increase in the Research and Development Expenditure Credit (“RDEC”) regime. In addition, there is a refocus of relief towards U.K. activity and therefore costs outside the U.K. are expected to be restricted going forward with further changes anticipated following a government consultation being launched with the intention of merging the SME and RDEC schemes.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
In the event that our NOL carryforwards or other tax attributes are subject to future limitation (including due to an ownership change under Sections 382 and 383 of the Code), deductions are not generated as expected, or if one or more of our tax positions are successfully challenged by the IRS or other tax authorities (in a tax audit or otherwise), our future tax liabilities may be greater than expected, which could adversely affect our operating results and cash flows.
Read it in 10-K Feb 24, 2025 at sec.gov
RewordedRisk Factors
These include, but are not limited to BNT327, pumitamig (BNT327), which is owned by BioNTech SE, SE and being developed in a collaboration with Bristol Myers Squibb Co. since June 2025, which has begun conducting Phase III clinical studies globally, and PF-08634404 (PF’4404 / SSGJ-707), which was licensed globally, ex-China by Pfizer Inc. in July 2025, LM-299, which was licensed globally by Merck & Co., Inc. in November 2024. 2024, and RC148, which was licensed outside of Greater China by AbbVie Inc. in January 2026.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
We expect that if our clinical product candidates continue to progress in development, and we continue to build our clinical operations and invest in our commercial operations, we will require significant additional investment in personnel, infrastructure and resources, Our ability to achieve our research, development and commercialization objectives depends on our ability to respond timely and effectively to these demands and expand our internal organization, systems and controls to accommodate additional anticipated growth.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
We expect that if our clinical product candidates continue to progress in development, and we continue to build our clinical operations and invest in our commercial operations, we will require significant additional investment in personnel, infrastructure and resources, Our ability to achieve our research, development and commercialization objectives depends on our ability to respond timely and effectively to these demands and expand our internal organization, systems and controls to accommodate additional anticipated growth. resources.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Our failure, or the failure of our third-party manufacturers, including Akeso, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
If a natural disaster, power outage, or other event occurred that prevented us from using all us, or a significant portion of our offices or prevented a third party on whom we rely rely, from using its offices or other facilities, or if a disaster damaged infrastructure critical infrastructure that we and third parties rely upon, to such offices or facilities, or if a disaster otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for extended periods period of time.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
The License Agreement, as amended, calls for initial consideration payments of $515 million (of which $500 million was paid in 2023 and $15 million was paid in 2024), as well as total contingent payments by the Company of up to $4.56 billion, as Akeso will be eligible to receive regulatory milestones of up to $1.05 billion and commercial milestones of up to $3.51 billion, many some of which will be due before the Company anticipates generating any revenue from the License Agreement. and commercial milestones of up to $3.51 billion.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
On the other hand, the Company More recent political developments could mean that we could face criticism from certain “anti-ESG” parties parties, including various governmental agencies, if it we were to make environmental or social commitments or pursue certain environmental or social initiatives that are alleged to be inherently political or polarizing in nature and could subject the Company to pressure in the media or through other means, which could adversely affect our reputation, business, financial performance, market access and growth.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Generally, worldwide economic conditions remain uncertain, particularly due to the effects of the conflict between Russia and Ukraine and Ukraine, the conflicts in the Middle East, including those in Gaza, Lebanon and Yemen, the escalating tensions in Venezuela and Greenland, and disruptions in the banking system and financial markets, including those in Japan, increased inflation and rising interest rates.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
The failure by If our management team were to fail to apply these funds effectively effectively, such failure could result in financial losses that could have a material adverse effect on our business, cause the market price of our shares of common stock to decline and delay the development of our product candidates.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Further, the effect of any such new tariffs or actions on our industry or customers, and customers whether they may be subject to any exceptions, is unknown and difficult to predict.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the U.S. and the U.K., and authorities in the E.U., including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as regulations (collectively, the "Trade “Trade Control laws". laws”).
Read it in 10-K Feb 23, 2026 at sec.gov
Quiet changesRisk Factors
The Company’s reputation or relationships with its stakeholders and other third parties could also be adversely impacted as a result of, among other things, (i) stakeholder or third-party perceptions of certain statements, if any, made by the Company, its employees, agents, any industry trade associations, or other third parties; or (ii) public pressure from investors or policy groups to change the Company's policies.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
In October 2024, the Company completed enrollment in its HARMONi clinical trial. In May 2025, we announced topline results from our multiregional, double-blinded, placebo-controlled, Phase III study HARMONi. At the prespecified primary data analysis, ivonescimab in combination with chemotherapy demonstrated a statistically significant improvement in PFS, the magnitude of which we believe to be clinically meaningful, with a hazard ratio of 0.52 (95% CI: 0.41 – 0.66; p<0.00001) compared to placebo in combination with chemotherapy; median PFS was 6.8 months for those patients receiving ivonescimab plus chemotherapy compared to 4.4 months for those receiving chemotherapy. PFS was assessed by BICR.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
We believe the PFS hazard ratio that was observed in both Asian and Western sub-populations to be clinically meaningful. The primary analysis demonstrated the consistency of the magnitude of the PFS benefit between patients randomized in Asian and Western territories, as well as the consistency in a single-region study (HARMONi-A) with this multiregional study.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
In a longer-term follow-up of PFS, which included all Western patients and at least six months of follow-up time for all patients, ivonescimab plus chemotherapy demonstrated a consistent hazard ratio in PFS as the primary PFS analysis observed HR = 0.57; 95% CI: 0.46 – 0.71). With the longer-term follow-up analysis, consistency of the magnitude of PFS benefit was demonstrated between patients randomized in Asia and Western patients when measured by hazard ratio. This longer-term follow-up analysis of PFS was performed at the time of the primary OS analysis.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
Ivonescimab in combination with chemotherapy showed a positive trend in OS in the primary analysis without achieving a statistically significant benefit with a hazard ratio of 0.79 (95% CI: 0.62 – 1.01; p=0.057). This trend provides further support for its use in EGFRm NSCLC post-TKI therapy, a setting where high unmet need continues to exist with limited approved options in the United States and other western territories. Currently there are no FDA-approved regimens that have demonstrated a statistically significant OS benefit in this patient setting. Both Asian and North American patients demonstrated a positive trend in OS. The results of the primary analysis in this multiregional study were consistent with that of the single-region randomized Phase III HARMONi-A study, which demonstrated a statistically significant OS benefit with a hazard ratio of 0.74 in the primary OS analysis in a similar patient population.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
In September 2025, an additional ad hoc OS analysis was performed for the HARMONi study, whereby the Western patients were followed for a longer period of time (Asian patients were locked at the time of the primary analysis). In this analysis that included longer-term follow-up of Western patients (median follow-up time of Western patients of 13.7 months), a hazard ratio consistent with the primary analysis was observed with an improved nominal p-value (HR=0.78; 95% CI: 0.62 – 0.98; nominal p=0.0332). Median OS for this analysis remained the same in both arms as was observed in the primary analysis. Median OS in Western patients receiving ivonescimab was 17.0 months compared to 14.0 months for those receiving placebo (HR=0.84); median OS in North American patients, specifically, had not yet been reached in the ivonescimab arm compared to 14.0 months in the placebo arm (HR=0.70). The hazard ratios for Western patients in totality, as well as patients from the North American and European regions individually, improved from the primary OS analysis to the analysis with longer-term follow-up of Western patients. Consistent benefit was observed across pre-defined subgroups.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
The dual primary endpoints were allocated separate alpha levels and tested individually. The alpha was recycled from the PFS to the OS analysis upon the successful achievement of the PFS endpoint.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
Based on the results of the HARMONi clinical trial, we submitted a BLA in the fourth quarter of 2025 in order to seek approval for ivonescimab plus chemotherapy for this proposed indication. The positive results of the multiregional Phase III study are detailed further under “Product Pipeline” below. As previously disclosed, the FDA noted that a statistically significant OS benefit is necessary to support marketing authorization in this setting. After careful consideration of the safety and efficacy profile of the current FDA-approved options for patients in this setting, the positive results of the Phase III multiregional study, including regional consistency, as well as discussions with key opinion leaders and those physicians who have administered ivonescimab to patients in a clinical study setting, we believe that the safety and efficacy data generated in the HARMONi study demonstrates that the ivonescimab regimen offers a potential treatment option for patients impacted by EGFR-mutant NSCLC in this setting with a favorable benefit-risk profile despite the lack of a statistically significant OS benefit. Summit announced in January 2026 that the FDA accepted for filing the BLA seeking approval for ivonescimab in combination with chemotherapy for this proposed indication. The FDA noted it intends to perform a complete review of the accepted and filed BLA, including planned mid-cycle and wrap-up meetings, and, subject to major deficiencies not being identified during the FDA’s review, proposed labeling, prior to the Prescription Drug User Fee Act goal action date of November 14, 2026.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
On August 11, 2025, we entered into an amendment (the “Amendment”) to the distribution agreement, which amended that certain distribution agreement, dated May 13, 2024, by and between us and sales agent (the “Original Distribution Agreement” and, as amended by the Amendment, the “Distribution Agreement”). Pursuant to the Amendment, the Original Distribution Agreement was amended to, among other things, increase the aggregate offering price of shares of the Company’s common stock, par value $0.01 per share, from time to time, through the sales agent, by up to an additional $360.0 million. The remaining gross proceeds available under the Distribution Agreement as of December 31, 2025 was approximately $299.3 million.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
On March 17, 2025, Rainaldi Revocable Trust, a purported stockholder of the Company, filed a derivative lawsuit in the Delaware Court of Chancery against certain of the Company’s current and former directors and the Company, solely as a nominal defendant, concerning the December 2022 Notes entered into by the Company, Mr. Duggan and Dr. Zanganeh in connection with the License Agreement. The suit asserts claims for breach of fiduciary duty and unjust enrichment and seeks, among other things, unspecified damages, rescission of the shares that Mr. Duggan and Dr. Zanganeh received as part of prepaid interest payments under the December 2022 Notes, as well as attorneys’ fees and costs.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
Pursuant to the December 2022 Notes, the Company obtained $520 million in bridge financing through three unsecured promissory notes: (1) a $400 million note issued to Mr. Duggan due on February 15, 2023; (2) a $20 million note issued to Dr. Zanganeh due on February 15, 2023; and (3) a $100 million note issued to Mr. Duggan due on September 15, 2023 (the “$100 Million Note”). The notes had an interest rate of 7.5% through February 15, 2023, with prepaid interest through that date paid in shares valued at $0.7913 per share. For periods after February 15, 2023, interest would accrue at the U.S. prime interest rate plus 50 basis points for three months, and thereafter at the U.S. prime rate plus 300 basis points. The notes contained no warrant coverage and no security interests. The Company announced the 2023 Rights Offering on December 6, 2022, which ran from February 7 through March 1, 2023. The 2023 Rights Offering was fully subscribed, with stockholders purchasing 476,190,471 shares of the Company’s common stock at $1.05 per share, raising $500 million in gross proceeds. Mr. Duggan and Dr. Zanganeh fully subscribed to their basic subscription rights, with Mr. Duggan participating by purchasing 376,489,880 shares for approximately $395.31 million. Following the Company’s fully subscribed $500 million 2023 Rights Offering, Dr. Zanganeh’s $20 million note was repaid on February 15, 2023, and Mr. Duggan's $400 million note was repaid. In the interest of minimizing stockholders dilution, the $100 Million Note was extended, and eventually the $75.5 million repayment was funded through the proceeds of the September 2024 Private Placement in which Mr. Duggan purchased 3,325,991 shares for an aggregate purchase price of $75.5 million as a participant in the September 2024 Private Placement at a purchase price of $22.70 per share, and the remaining $24.5 million was repaid in full on October 1, 2024, along with $7.3 million in accrued interest. Defendants’ motion to dismiss the complaint was filed on May 16, 2025 (the “Motion to Dismiss”). Plaintiff filed a motion to certify certain constitutional questions to the Delaware Supreme Court on May 29, 2025 (the “Motion to Certify”). Defendants agreed to a stipulation staying briefing on the Motion to Certify and the Motion to Dismiss pending the Delaware Supreme Court’s decision in another case involving substantially the same constitutional questions. On June 18, 2025, the Court granted such stipulation.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
On June 18, 2025, an unknown third party filed a notice of opposition against the Company’s in-licensed EP3882275B1 patent (the “’275 patent”) in the European Opposition Division of the European Patent Office (“EPO”). The ’275 patent covers Ivonescimab. The notice primarily asserts that the 275 patent lacks inventive step. The Company contests these assertions and worked with its collaboration partner, Akeso, to timely file a response before the European Opposition Division of the EPO on January 2, 2026.
Read it in 10-K Feb 23, 2026 at sec.gov
RemovedMD&A
In October 2024, the Company completed enrollment in its HARMONi clinical trial. The Company expects to disclose topline results from HARMONi in mid-2025, depending upon maturation of the data per the protocol.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
Other operating (expense) income, net consists primarily of research and development ("R&D") tax credits received in the United Kingdom (“U.K.”). We benefit from two U.K. research and development tax credit cash rebate regimes: Small and Medium Enterprise Program (“SME Program”) and the Research and Development Expenditure Credit Program (“RDEC Program”). Under both schemes, we receive cash payments that are not dependent on our pre-tax net income levels.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
Based on criteria established by His Majesty’s Revenue and Customs (“HMRC”), a portion of expenditures being carried out in relation to our pipeline research and development, clinical trials management and third-party manufacturing development activities are eligible for the SME regime tax credits and amounts recognized from grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organizations.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
Our investment in ivonescimab included $520.9 million for the year ended December 31, 2023 related to our upfront milestone payments pursuant to the License Agreement with Akeso. The License Agreement closed in January 2023, and both Akeso and Summit entered into the Common Stock Issuance Agreement (“Issuance Agreement”). Pursuant to the License Agreement and Issuance Agreement, Akeso elected to receive 10 million shares of our common stock in lieu of $25.1 million cash and was paid $274.9 million in cash as the initial upfront payment. The remaining $200.0 million upfront payment was paid on March 6, 2023. Acquired in-process research and development expense comprised of the $474.9 million paid in cash, the fair value of the 10 million shares of common stock on the date of closing the transaction of $45.9 million, and $0.1 million of direct transactions costs incurred.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
U.K. research and development tax credits decreased by $0.7 million for the year ended December 31, 2024, compared to the same period in the prior year, as management updated its estimates for qualifying expenditures relating to ivonescimab, which resulted in a decrease in tax credits claimed.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
Our certificate of incorporation provides that it will indemnify the directors and officers to the fullest extent permitted by Delaware law. In addition, we have entered into indemnification agreements with all of the directors and executive officers. These indemnification agreements may require us, among other things, to indemnify each such director or executive officer for some expenses, including attorneys’ fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers. We believe the fair value for these indemnification obligations is minimal. Accordingly, we have not recognized any liabilities relating to these obligations as of December 31, 2024.
Read it in 10-K Feb 24, 2025 at sec.gov
RewordedMD&A
Net cash provided by financing activities for the year ended December 31, 2024 2025 was $381.2 $617.5 million and was primarily due to $434.9 million consisted of proceeds from various a private placements, $43.0 placement of $500.0 million, $104.5 million net proceeds from our current ATM Distribution Agreement, $7.3 million of proceeds received related to the exercise of warrants and proceeds received of $2.7 $5.7 million related to employee stock awards, partially offset by a $100.0 million early principal payment on promissory notes payable to a related party. awards and purchase plans.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Research and development $ 537.7 $ 150.8 $ 59.4 $ 91.4 386.9 Acquired in-process research and development — 15.0 520.9 (505.9) (15.0) General and administrative 60.5 30.3 30.2 556.7 60.2 496.5 Total operating expenses 226.3 610.6 (384.3) Other operating income, net 0.3 1.0 (0.7) Operating loss (226.0) (609.6) 383.6 1,094.4 226.0 868.4 Other income, net 14.8 13.4 11.2 2.2 1.4 Interest expense — (8.7) (16.5) 7.8 8.7 Net loss $ (221.3) 1,079.6 $ (614.9) 221.3 $ 393.6 858.3
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Additionally, compensation-related In addition, compensation related costs, excluding stock-based compensation compensation, increased by $4.6 $8.2 million, for the year ended December 31, 2024, 2025, compared to the same period in the prior year, as the Company is focused on building its executive management team and legal fees and professional services increased by $6.4 million for the year ended December 31, 2025, compared to the same period in the prior year to continue supporting its growth. the development of ivonescimab.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
(in millions) Year Ended December 31, (in millions) 2025 2024 2023 $ Change Oncology clinical trial related costs $ 266.4 $ 100.9 $ 35.2 $ 65.7 165.5 Acquired in-process research and development — 15.0 520.9 (505.9) Anti-infectives (1) 0.3 (1.5) 1.8 (15.0) Compensation related costs, excluding stock-based compensation 33.6 21.3 12.3 52.7 33.9 18.8 Stock-based compensation 218.6 16.0 4.4 11.6 202.6 Total $ 537.7 $ 165.8 $ 580.3 $ (414.5) 371.9
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
To date, we have financed our operations primarily through issuances of our common stock, including our most recent private placement placements issued in October 2025 and September 2024 for gross proceeds of $235.0 $500.0 million and the raise of $44.2 million gross proceeds from our ATM Agreement during 2024, issuance of debt, and receipt of payments to us under license and collaboration arrangements. $235.0 million, respectively,
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Non-cash The non-cash charges primarily include $51.0 consisted of $732.4 million of stock-based compensation, compensation driven by the modification to outstanding performance-based stock option awards which removed the performance-based vesting criteria, partially offset by $2.6 $7.0 million related relating to the amortization of the discount on short-term investments. investments in U.S.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Additionally, compensation-related costs, excluding stock-based compensation General and administrative expenses increased by $4.6 million, $496.5 million for the year ended December 31, 2024, 2025, compared to the same period in the prior year, as the Company is focused on building its executive management team to continue supporting its growth. year.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Interest expense on promissory notes payable to related parties decreased to $8.7 million for the year ending December 31, 2024, from $16.5 million during 2025 compared to the year ending December 31, 2023, same period in the prior year, due to the repayment in full payment of the promissory note in October 2024.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
(in millions) Year Ended December 31, (in millions) 2025 2024 2023 $ Change Compensation related costs, excluding stock-based compensation $ 22.9 $ 14.7 $ 10.1 $ 4.6 8.2 Stock-based compensation 513.8 35.0 9.7 25.3 478.8 Legal fees and professional services 11.2 4.8 6.9 (2.1) 6.4 Other general and administrative expenses 6.0 3.6 2.4 8.8 5.7 3.1 Total $ 60.5 556.7 $ 30.3 60.2 $ 30.2 496.5
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
On June 3, 2024, the Company entered into an amendment to the License Agreement Second Amendment with Akeso to expand its territories covered under the License Agreement to also include the Latin America, including Mexico and all countries in Central America and South America, the Middle East and Africa regions (collectively, and as expanded, the "Licensed Territory"). Africa.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
For a discussion and analysis of our financial condition and results of operations for the year ended December 31, 2023 2024 compared to December 31, 2022, 2023, please refer to Item 7 of Part II, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023, 2024, which was filed with the SEC on February 24, 2025, and is available on the SEC’s website at www.sec.gov and our Investor Relations website at www.smmttx.com/investor-information.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Other income (expense), income, net increased by $2.2 $1.4 million for the year ended December 31, 2024, 2025, compared to the same period in the prior year, primarily due to an increase of $3.0 $2.0 million in interest income due to the higher cash equivalents and short-term investments balance, partially offset by unfavorable changes in foreign currency losses of $0.7 million. balance.
Read it in 10-K Feb 23, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SMMT/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.